TICKERNERD
Menu
AVTXAVTXHealthcare · Biotechnology

AVTX Stock Forecast: Avalo Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$20
+0.05% on the day

The 15 Wall Street analysts covering Avalo Therapeutics, Inc. hold a median 12-month price target of $42 — +111.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 43 of 100 as at 22 Aug 2026 — in the lower half.

Market cap
$1.1B
Ticker Nerd rank
43 / 100
Median analyst target
$42
Analysts covering
15
Total return, dividends reinvested
1W
+1.2%
1M
+5.4%
YTD
+9.2%
1Y
+111.6%
From 52W high
−13.3%
From 52W low
+119.8%
$9
$23
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

AVTX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Avalo Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
43 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
94
Quality
65
Value
49
Accruals
45
Size
45
Growth
43
Revisions
42
Volatility
32
Issuance
25

Momentum (94): The shares have been drifting up relative to others.

Issuance (25): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

AVTX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on AVTX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$20$30$40$50$60Oct 25Jan 26Apr 26Jul 26AVTXHigh $60Median $42Low $30

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says15 analysts
15 Buy0 Hold0 Sell
Low $30Median $42High $60

The green dot is the last close — the median target sits +111.8% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
7 Aug 2026GuggenheimMaintainsBuy$50 → $48
7 Aug 2026HC Wainwright & Co.MaintainsBuy$35 → $30
6 July 2026Leerink PartnersInitiatesOutperform$38
6 July 2026Leerink PartnersInitiatesOutperform—
16 June 2026BTIGReiteratesBuy—
12 June 2026B of A SecuritiesInitiatesBuy—
14 May 2026CitizensMaintainsMarket Outperform—
14 May 2026HC Wainwright & Co.MaintainsBuy—
14 May 2026MizuhoMaintainsOutperform—
14 May 2026WedbushMaintainsOutperform—
11 May 2026Piper SandlerMaintainsOverweight—
6 May 2026BTIGMaintainsBuy—
6 May 2026CitizensMaintainsMarket Outperform—
6 May 2026WedbushMaintainsOutperform—
13 Apr 2026BTIGReiteratesBuy—
9 Apr 2026Wolfe ResearchInitiatesOutperform—
6 Apr 2026CitizensInitiatesMarket Outperform—
25 Mar 2026HC Wainwright & Co.MaintainsBuy—
24 Mar 2026BTIGReiteratesBuy—
2 Feb 2026GuggenheimInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. AVTX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

AVTX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
3
Fundamentals

Avalo Therapeutics, Inc. (AVTX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
2.3×

Cheaper than 69% of US stocks

Price / sales
18025.1×

Cheaper than 1% of US stocks

Price / book
2.3×

Cheaper than 42% of US stocks

EV / EBITDA
−7.3×

Cheaper than 81% of US stocks

Growth & margins
Revenue growth (YoY)
−100.0%

Higher than 1% of US stocks

Earnings growth (YoY)
—
Gross margin
—
Operating margin
−154847.5%

Higher than 1% of US stocks

Net margin
100.0%

Higher than 99% of US stocks

Returns & dividend
Return on equity
−36.3%

Higher than 25% of US stocks

Return on assets
−18.5%

Higher than 20% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

AVTX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
AVTXAvalo Therapeutics, Inc.$1.1B
43
JANXJanux Therapeutics, Inc.$1.0B
74
KURAKura Oncology, Inc.$1.1B
80
ABUSArbutus Biopharma Corp.$1.0B
97
LXRXLexicon Pharmaceuticals, Inc.$1.0B
68
WVEWave Life Sciences, Inc.$1.0B
16
CLYMClimb Bio, Inc.$989.5M
61

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Avalo Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest AVTX news & analysis

Avalo Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Updates

GlobeNewsWire · 6 Aug 2026neutral

Avalo Therapeutics, Inc., a clinical-stage biotechnology company focused on IL-1β pathway therapeutics for immune-mediated inflammatory diseases, announced its business updates and financial results for the second quarter of 2026 on August 6, 2026.

Why it matters — For those tracking AVTX, the release provides an official update on the company's recent business activities and second-quarter 2026 financial position.

FAQ

Frequently asked questions about AVTX stock

What is the AVTX stock price forecast for 2026-2027?

The 15 Wall Street analysts covering Avalo Therapeutics, Inc. have a median 12-month price target of $42, with estimates ranging from $30 to $60. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is AVTX stock a buy right now?

Of the 15 analysts covering Avalo Therapeutics, Inc., 15 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Avalo Therapeutics, Inc. 43 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank AVTX?

As at 22 Aug 2026, Avalo Therapeutics, Inc. ranks 43 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (94 of 100).

Will AVTX stock go up?

No one can know that. What the data says: the median 12-month target from 15 analysts implies +111.8% from the last close, and Ticker Nerd's factor model ranks Avalo Therapeutics, Inc. 43 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the AVTX stock forecast for 2030?

No analyst covering Avalo Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AVTX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $30 to $60 over the next 12 months.

How has AVTX stock performed over the past year?

Avalo Therapeutics, Inc. returned +111.6% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Avalo Therapeutics, Inc. do?

Avalo Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases with significant unmet needs.

What is the latest news on AVTX?

The most recent item we track (GlobeNewsWire, 6 Aug 2026): "Avalo Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Updates". Avalo Therapeutics, Inc., a clinical-stage biotechnology company focused on IL-1β pathway therapeutics for immune-mediated inflammatory diseases, announced its business updates and financial results for the second quarter of 2026 on August 6, 2026.

Company

About Avalo Therapeutics, Inc.

Avalo Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases with significant unmet needs. The company targets the IL-1β pathway, a central driver of inflammation, through its lead asset, abdakibart (AVTX-009), a humanized monoclonal antibody currently in a Phase 2 LOTUS trial for hidradenitis suppurativa, a chronic inflammatory skin condition. Avalo Therapeutics Inc. is exploring the potential of AVTX-009 in additional immune-mediated indications to address broader patient populations. Founded in 2011 and headquartered in Wayne, Pennsylvania, the company focuses on advancing novel therapeutics driven by scientific innovation and compassion for those affected by chronic inflammatory conditions. Its pipeline emphasizes best-in-class medicines to transform lives in areas lacking effective therapies, operating within the health technology sector to develop and potentially commercialize targeted biologics for immune dysregulation.

CEO Dr. Garry A. Neil M.D. · 23 employees · United States · https://www.avalotx.com